Sinphar Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018
November 12, 2018 at 04:42 pm EST
Share
Sinphar Pharmaceutical Co. Ltd. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced sales was TWD 527.901 million compared to TWD 533.634 million a year ago. Operating loss was TWD 44.722 million compared to TWD 10.374 million a year ago. Net loss was TWD 14.369 million compared to net income of TWD 14.011 million a year ago. Basic loss per share was TWD 0.09 compared to basic earnings per share of TWD 0.08 a year ago. For the nine months, sales was TWD 1,617.367 million compared to TWD 1,565.711 million a year ago. Operating loss was TWD 85.614 million compared to TWD 60.616 million a year ago. Net income was TWD 1.060 million compared to TWD 14.493 million a year ago. Basic earnings per share was TWD 0.01 compared to TWD 0.09 a year ago.
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Companyâs principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
SINPHAR PHARMACEUTICAL CO.,LTD. 
